6:36 PM
 | 
Nov 14, 2007
 |  BC Extra  |  Company News

Avandia gets stronger warning

FDA and GlaxoSmithKline (LSE:GSK; GSK) announced Wednesday an agreement to supplement the existing boxed warning for Avandia rosiglitazone to include new language noting that it has been associated with a potential increase in the risk of myocardial ischemic events such as angina or myocardial infarction. The risk was detected in a meta-analysis of short-term studies comparing Avandia to placebo, the label notes. It states that three...

Read the full 320 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >